Details of the Drug Reposition

General Information of This Drug (ID: DMONWJ4)

Drug Name
Imetelstat   DMONWJ4
Synonyms
Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 2/3 [1]
------------------------------------------------------------------------------------
5 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelofibrosis DISIMP21 2A20.2 Phase 2 [1]
Multiple myeloma DISEWP9B 2A83 Phase 2 [2]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 2 [2]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
Essential thrombocythemia DISWWK11 3B63.1Z Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02426086) Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. U.S. National Institutes of Health.